CYP2C19 and ischemic stroke: These include the accessibility of effective secondary prevention, CYP2C19 genetic makeup, consistent rehabilitation practices, familial backing, the gravity of ischemic stroke, and the kind of acute phase therapy employed (25, 33–35).